Cannabinoids control spasticity and tremor in a multiple sclerosis model

Nature

Volumn 404, Issue 6773, 2000, Pages 84-87

  Baker, David ^a,b   Pryce, Gareth ^a,b   Ludovic Croxford, J ^a,b   Brown, Peter ^c   Pertwee, Roger G ^d   Huffman, John W ^e   Layward, Lorna ^f  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^d UNIVERSITY OF ABERDEEN   (United Kingdom)

^e CLEMSON UNIVERSITY   (United States)

^f Great Britain and Northern Ireland   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID; CANNABINOID RECEPTOR; METHANANDAMIDE; MYELIN; RIMONABANT; TETRAHYDROCANNABINOL;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; SPASTICITY; TREMOR;

ANIMALS; BORNANES; CANNABINOIDS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; MICE; MULTIPLE SCLEROSIS; PIPERIDINES; PYRAZOLES; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; SPASM; TREMOR;

ANIMALIA; CANNABIS;

EID: 0034594905     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/35003583     Document Type: Article

References (20)

1. Baker, D. et al. Induction of chronic relapsing experimental allergic encephalomyelitis in Biozzi mice. J. Neuroimmunol. 28, 261-270 (1990).
2. Consroe, P., Musty, R., Rein, J., Tillery, W. & Pertwee, R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur. Neurol. 38, 44-48 (1997).
3. Consroe, P. Cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol. Dis. 5, 534-551 (1998).
4. 9-tetrahydrocannabinol. J. Clin. Pharmacol. 21 (suppl.), 413-416 (1981).
5. Clifford, D. B. Tetrahydrocannabinol for tremor in multiple sclerosis. Ann. Neurol. 13, 669-671 (1983).
6. 9-THC in the treatment of spasticity associated with multiple sclerosis. Adv. Alcohol Substance Abuse 7, 39-50 (1987).
7. Martyn, C. N., Illis, L. S. & Thom, J. Nabilone in the treatment of multiple sclerosis. Lancet 345, 579 (1995).
8. Pertwee, R. G. Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem. 6, 635-664 (1999).
9. 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J. Neuroimmunol. 23, 73-81 (1989).
10. Wirguin, I. et al. Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology 28, 209-214 (1994).
11. Heller, A. H. & Hallet, M. Electrophysiological studies with the spastic mutant mouse. Brain Res. 234, 299-308 (1982).
12. Chai, C. K. Hereditary spasticity in mice. J. Heredity 52, 241-243 (1961).
13. Pertwee, R. G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Therapeut. 74, 129-180 (1997).
14. Breivogel, C. S. & Childers, S. R. The functional neuroanatomy of brain cannabinoid receptors. Neurobiol. Dis. 5, 417-431 (1998).
15. Landsman, R. S., Burkey, T. H., Consroe, P., Roeske, W. R. & Yamamura, H. I. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur. J. Pharmacol. 334, R1-R2 (1997).
16. Portier, M. et al. SRI44528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist. J. Pharmacol Exp. Ther. 288, 582-589 (1999).
17. Calignano, A., La Rana, G., Giuffrida, A. & Piomelli, D. Control of pain initiation by endogenous cannabinoids. Nature 394, 277-281 (1998).
18. Giuffrida, A. et al. Dopamine activation of endogenous cannabinoid signalling in dorsal striatum. Nature Neurosci. 2, 358-363 (1999).
19. 2 receptor. Bioorg. Med. Chem. 7, 2905-2914 (1999).
20. Noth, J. Trends in the pathophysiology and pharmacotherapy of spasticity. J. Neurol. 238, 131-139 (1991).